TriStar offers quantitative digital pathology services for integrated projects to enumerate and localize target expression in TMAs & whole tissue sections. Digital image analysis is assisted throughout by TriStar’s medical pathologists to ensure evaluation of relevant regions of interest, optimal algorithm performance and data interpretation.
Our Team is experienced in digital image analysis of TMAs and correlation with molecular and clinical annotations.
Benefits of choosing Tristar’s services
Whole slide scanner
TriStar provides whole slide digital images for all integrated service projects.
Digital pathology services
TriStar utilizes open source image analysis solutions (QuPath & CellProfiler) in addition to Indica Labs Halo image analysis platform.
TriStar delivers pathologist-assisted digital image analysis to generate biologically relevant biomarker data.
Digital Spatial Profiling
Analyze targets & spatial relationships in context of TME with CODEX & Nanostring GeoMx DSP.
Define Your Project Requirements
We will sit down with you and work out exactly what the objective of your project is as well as the parameters to work within.
We will source the right samples from within our repositories and network.
We will put together the right team and platforms to complete your project correctly and on time.
Confirm & Start Project
A Statement of Work that includes a project plan, deliverables, costs and timelines will be discussed and agreed upon.
IO Multi tumor array set of 6 TMAs with histopath data (TA3124-3129), 1x1mm core each from tumor & invasive edge
NSCLC with 2nd line IO follow up & optional RNAseq, GeoMx (protein & RNA panels), DAB IHC data (TA4301)
Head & neck SCC with IO treatment follow up data (TA4357)
Ovarian cancer pre and post platinum treatment (not donor matched) with follow up data (TA4326)
Our experienced ex-pharma scientists & pathologists specialize in IHC assay development, and protocol optimization & analysis to deliver robust data while accelerating project decisions.
TriStar’s services can be used to guide patient selection for projects & inform the path to clinical development. TMAs and/or FFPE blocks can be combined into sets to screen 150-1500 donor samples per indication.